Anti-Helicobacter pylori seropositivity: Influence on severity and treatment response in patients with chronic hepatitis C

Journal of Viral Hepatitis

Volumn 14, Issue 1, 2007, Pages 48-54

  Umemura, T ^a   Muto, H ^a   Tanaka, E ^a   Matsumoto, A ^a   Ichijo, T ^a   Yoshizawa, K ^a   Akamatsu, T ^a   Kiyosawa, K ^a   Tanaka, Naoki ^a   Misawa, Noriko ^a   Orii, Koji ^a   Imai, Yasuharu ^b   Wada, Shuichi ^c   Nakatsuji, Yoshiyuki ^d   Miyabayashi, Chiharu ^e   Imai, Haruhiko ^f   Takamatsu, Masato ^g   Sodeyama, Takeshi ^h   Kobayashi, Masakazu ^h   Furuta, Kiyoshi ^h   Gibo, Yukio ^h   Usuda, Seiichi ⁱ   Urushibara, Akihiko ^j   Yoda, Hidetoshi ^k   Tsukadaira, Toshihisa ^l   Koike, Yuriko ^m   Arai, Kaoru ⁿ   Okiyama, Wataru ^o   Maruyama, Atsushi ^p   Yamaura, Takahiro ^q   Iijima, Akihiro ^r   more..

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Nagano Municipal Hospital   (Japan)

^c Nagano Redcross Hospital   (Japan)

^d Shinshu Ueda Medical Center   (Japan)

^e Chikuma Central Hospital   (Japan)

^f Yodakubo Hospital   (Japan)

^g Nagano Prefectural Federation of Agricultural Cooperative for Health and Welfare   (Japan)

^h National Hospital Organization Matsumoto Medical Center Matsumoto Hospital   (Japan)

ⁱ Aizawa Hospital   (Japan)

^j Tatsuno Hospital   (Japan)

^k National Hospital Organization   (Japan)

^l Kenwakai Hospital   (Japan)

^m Kawanakajima Clinic   (Japan)

ⁿ Hata Hospital   (Japan)

^o Suwa Red Cross Hospital   (Japan)

^p Showainan Hospital   (Japan)

^q Iida Municipal Hospital   (Japan)

^r Kiso Prefecture Hospital   (Japan)

more..

Author keywords

Helicobacter pylori; Hepatitis C virus; Interferon; Ribavirin; Thrombocytopenia

Indexed keywords

ALPHA2B INTERFERON; HEPATITIS C ANTIBODY; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BLOOD SAMPLING; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME IMMUNOASSAY; FEMALE; FIBROSIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HEPATITIS C; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS INFECTION;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLATELET COUNT; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 33845752055     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2006.00770.x     Document Type: Article

References (41)

1. Alter HJ, Purcell RH, Shih JW et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989; 321: 1494-1500.
2. Kiyosawa K, Sodeyama T, Tanaka E et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671-675.
3. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000; 20: 17-35.
4. Kiyosawa K, Umemura T, Ichijo T et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004; 127: S17-S26.
5. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492.
6. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-1432.
7. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
8. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
9. Chen SY, Liu TY, Chen MJ, Lin JT, Sheu JC, Chen CJ. Seroprevalences of hepatitis B and C viruses and Helicobacter pylori infection in a small, isolated population at high risk of gastric and liver cancer. Int J Cancer 1997; 71: 776-779.
10. Fujisawa T, Kumagai T, Akamatsu T, Kiyosawa K, Matsunaga Y. Changes in seroepidemiological pattern of Helicobacter pylori and hepatitis A virus over the last 20 years in Japan. Am J Gastroenterol 1999; 94: 2094-2099.
11. Pellicano R, Leone N, Berrutti M et al. Helicobacter pylori seroprevalence in hepatitis C virus positive patients with cirrhosis. J Hepatol 2000; 33: 648-650.
12. Zucca E, Roggero E, Maggi-Solca N et al. Prevalence of Helicobacter pylori and hepatitis C virus infections among non-Hodgkin's lymphoma patients in Southern Switzerland. Haematologica 2000; 85: 147-153.
13. Durazzo M, Pellicano R, Premoli A et al. Helicobacter pylori seroprevalence in patients with autoimmune hepatitis. Dig Dis Sci 2002; 47: 380-383.
14. Dore MP, Realdi G, Mura D, Graham DY, Sepulveda AR. Helicobacter infection in patients with HCV-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Dig Dis Sci 2002; 47: 1638-1643.
15. Malaty HM, Tanaka E, Kumagai T et al. Seroepidemiology of Helicobacter pylori and hepatitis A virus and the mode of transmission of infection: a 9-year cohort study in rural Japan. Clin Infect Dis 2003; 37: 1067-1072.
16. Rocha M, Avenaud P, Menard A et al. Association of Helicobacter species with hepatitis C cirrhosis with or without hepatocellular carcinoma. Gut 2005; 54: 396-401.
17. Boomkens SY, Rave S, Pot RG et al. The role of Helicobacter spp. in the pathogenesis of primary biliary cirrhosis and primary sclerosing cholangitis. FEMS Immunol Med Microbiol 2005; 44: 221-225.
18. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435.
19. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-374.
20. Marchildon PA, Sugiyama T, Fukuda Y et al. Evaluation of the effects of strain-specific antigen variation on the accuracy of serologic diagnosis of Helicobacter pylori infection. J Clin Microbiol 2003; 41: 1480-1485.
21. Umemura T, Wang RY, Schechterly C, Shih JW, Kiyosawa K, Alter HJ. Quantitative analysis of anti-hepatitis C virus antibody-secreting B cells in patients with chronic hepatitis C. Hepatology 2006; 43: 91-99.
22. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 22-26.
23. Pontisso P, Ruvoletto MG, Fattovich G et al. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology 1993; 105: 1529-1533.
24. Vento S, Garofano T, Renzini C et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338: 286-290.
25. Tanaka E, Alter HJ, Nakatsuji Y et al. Effect of hepatitis G virus infection on chronic hepatitis C. Ann Intern Med 1996; 125: 740-743.
26. Umemura T, Yeo AE, Sottini A et al. SEN virus infection and its relationship to transfusion-associated hepatitis. Hepatology 2001; 33: 1303-1311.
27. Umemura T, Alter HJ, Tanaka E et al. Association between SEN virus infection and hepatitis C in Japan. J Infect Dis 2001; 184: 1246-1251.
28. Umemura T, Alter HJ, Tanaka E et al. SEN virus: response to interferon alfa and influence on the severity and treatment response of coexistent hepatitis C. Hepatology 2002; 35: 953-959.
29. Umemura T, Tanaka E, Ostapowicz G et al. Investigation of SEN virus infection in patients with cryptogenic acute liver failure, hepatitis-associated aplastic anemia, or acute and chronic non-A-E hepatitis. J Infect Dis 2003; 188: 1545-1552.
30. Sagnelli E, Coppola N, Scolastico C et al. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology 2000; 32: 1106-1110.
31. Jardi R, Rodriguez F, Buti M et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology 2001; 34: 404-410.
32. Tanaka E, Ohue C, Aoyagi K et al. Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA. Hepatology 2000; 32: 388-393.
33. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology 2002; 36: S121-S127.
34. Avenaud P, Marais A, Monteiro L et al. Detection of Helicobacter species in the liver of patients with and without primary liver carcinoma. Cancer 2000; 89: 1431-1439.
35. Nilsson HO, Mulchandani R, Tranberg KG, Stenram U, Wadstrom T. Helicobacter species identified in liver from patients with cholangiocarcinoma and hepatocellular carcinoma. Gastroenterology 2001; 120: 323-324.
36. Franchini M, Veneri D. Helicobacter pylori infection and immune thrombocytopenic purpura: an update. Helicobacter 2004; 9: 342-346.
37. Michel M, Cooper N, Jean C, Frissora C, Bussel JB. Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura? Blood 2004; 103: 890-896.
38. Stasi R, Rossi Z, Stipa E, Amadori S, Newland AC, Provan D. Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura. Am J Med 2005; 118: 414-419.
39. Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of 'hypersplenic' thrombocytopenia. J Clin Invest 1966; 45: 645-657.
40. Shimodaira S, Ishida F, Ichikawa N et al. Serum thrombopoietin (c-Mpl ligand) levels in patients with liver cirrhosis. Thromb Haemost 1996; 76: 545-548.
41. Kajihara M, Kato S, Okazaki Y et al. A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis. Hepatology 2003; 37: 1267-1276.